Squarepoint’s Achieve Life Sciences ACHV Stock Holding History

Squarepoint’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57.8K	Sell	19,658 -144,947	-88%	-$644K	﹤0.01%	4127
2025 Q4	$818K	Sell	164,605 -208,474	-56%	-$909K	﹤0.01%	2780
2025 Q3	$1.18M	Buy	373,079 +359,642	+2,677%	+$987K	﹤0.01%	2550
2025 Q2	$30.4K	Buy	+13,437	New	+$38.3K	﹤0.01%	4361
2025 Q1	–	Sell	-17,519	Closed	-$61.7K	–	4481
2024 Q4	$61.7K	Buy	+17,519	New	+$79.4K	﹤0.01%	4807
2024 Q1	–	Sell	-23,105	Closed	-$95.2K	–	3944
2023 Q4	$95.2K	Buy	23,105 +10,631	+85%	+$46.3K	﹤0.01%	3761
2023 Q3	$53.6K	Sell	12,474 -9,498	-43%	-$47.9K	﹤0.01%	3630
2023 Q2	$114K	Buy	+21,972	New	+$154K	﹤0.01%	3340
2020 Q4	–	Sell	-10,093	Closed	-$84K	–	2858
2020 Q3	$84K	Buy	+10,093	New	+$92.6K	﹤0.01%	2315

Other funds holding ACHV

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's ACHV Position: Q1 2026 in Review

Squarepoint reduced its Achieve Life Sciences (ACHV) stake by 88% in Q1 2026, selling an estimated $644K and leaving 19,658 shares worth $57.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4127.

Squarepoint first reported a position in ACHV in Q3 2020 and has held it in 9 quarters since. The position peaked at $1.18M in Q3 2025. 81 funds tracked by Wall St. Rank hold ACHV as of Q1 2026.

Squarepoint held 19,658 shares of Achieve Life Sciences worth $57.8K as of Q1 2026.
Squarepoint sold 144,947 Achieve Life Sciences shares in Q1 2026, an estimated $644K.
Achieve Life Sciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4127 holding.
Squarepoint first reported a position in Achieve Life Sciences in Q3 2020 and has held it in 9 quarters since.
Squarepoint's Achieve Life Sciences position peaked at $1.18M in Q3 2025.
81 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.